Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

649059.pdf (211.67 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2014-06-20

Llicència de publicació

cc-by-nc (c) Ascher-Svanum, H. et al., 2014
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/65757

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection 

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.2147/NDT.S61409

Resum

BACKGROUND: Little is known about the long-term changes in the functioning of schizophrenia patients receiving maintenance therapy with olanzapine long-acting injection (LAI), and whether observed changes differ from those seen with oral olanzapine. METHODS: This study describes changes in the levels of functioning among outpatients with schizophrenia treated with olanzapine-LAI compared with oral olanzapine over 2 years. This was a secondary analysis of data from a multicenter, randomized, open-label, 2-year study comparing the long-term treatment effectiveness of monthly olanzapine-LAI (405 mg/4 weeks; n=264) with daily oral olanzapine (10 mg/day; n=260). Levels of functioning were assessed with the Heinrichs-Carpenter Quality of Life Scale. Functional status was also classified as 'good', 'moderate', or 'poor', using a previous data-driven approach. Changes in functional levels were assessed with McNemar's test and comparisons between olanzapine-LAI and oral olanzapine employed the Student's t-test. RESULTS: Over the 2-year study, the patients treated with olanzapine-LAI improved their level of functioning (per Quality of Life total score) from 64.0-70.8 (P<0.001). Patients on oral olanzapine also increased their level of functioning from 62.1-70.1 (P<0.001). At baseline, 19.2% of the olanzapine-LAI-treated patients had a 'good' level of functioning, which increased to 27.5% (P<0.05). The figures for oral olanzapine were 14.2% and 24.5%, respectively (P<0.001). Results did not significantly differ between olanzapine-LAI and oral olanzapine. CONCLUSION: In this 2-year, open-label, randomized study of olanzapine-LAI, outpatients with schizophrenia maintained or improved their favorable baseline level of functioning over time. Results did not significantly differ between olanzapine-LAI and oral olanzapine.

Matèries

Antipsicòtics, Esquizofrènia, Qualitat de vida

Matèries (anglès)

Antipsychotic drugs, Schizophrenia, Quality of life

Citació

Col·leccions

Articles publicats en revistes (Psicologia Clínica i Psicobiologia)

Citació

ASCHER-SVANUM, Haya, et al. Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection . Neuropsychiatric Disease And Treatment. 2014. Vol. 10, num. 1125-1131. ISSN 1176-6328. [consulted: 19 of August of 2026]. Available at: https://hdl.handle.net/2445/65757

Exportar metadades

JSON - METS

Compartir registre